Faculty

Back to Index
Anthony Boutros El-Khoueiry, MD
Associate Professor of Clinical Medicine
Norris Cancer Center Ciso Chair
Medicine
NOR 3451 Health Sciences Campus Los Angeles
+1 323 865 3900

Overview

Anthony El-Khoueiry, MD, is an assistant professor of clinical medicine at the Keck School of Medicine of USC and director of clinical translation at the Southern California Clinical and Translational Science Institute (SC CTSI). He has extensive experience in clinical and translational research through his roles as medical director of the Clinical Investigations Support Office and director of the phase I drug development program at the USC Norris Comprehensive Cancer Center. He is the recipient of the National Cancer Institute Cancer Investigator Team Leadership Award in 2011.

Dr. El-Khoueiry has established a national reputation in clinical research-related hepatobiliary (liver, gall bladder and bile duct) and pancreatic cancers. He is a member of the National Cancer Institute Hepatobiliary Cancers Task Force and chair of the Southwest Oncology Group hepatobiliary cancers subcommittee. In addition, he is the principal investigator of several phase I, including first-in-human, clinical trials aimed at developing novel therapies for solid tumors. Dr. El-Khoueiry works with several basic scientists at USC on joint translational projects designed to identify molecular predictors of outcome and survival for patients with advanced gastrointestinal cancers.

Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at USC. He unravels scientific and non-scientific mysteries in four languages: English, Arabic, French and Spanish.

Awards

USC: Dean's Scholar, 1998

Southwest Oncology Group: Young Investigator Training Award, 2004

Division of Hematology: Researcher of the Year, 2003

National Cancer Institute : Clinical Investigator Team Leadership Award, 2011-2012

Publications

Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clin Cancer Res. 2016 May 15; 22(10):2368-76. View in: PubMed

Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol. 2015 Nov; 9(9):1799-814. View in: PubMed

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015 Aug 20; 33(24):2617-22. View in: PubMed

Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Pharmacogenomics J. 2015 Jun; 15(3):226-34. View in: PubMed

Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 2015 Mar; 4(2):115-25. View in: PubMed

Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar; 75(3):537-46. View in: PubMed

Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Mar 1; 21(5):1044-51. View in: PubMed

Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33(1):241-6. View in: PubMed

Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 9; 111(12):2268-74. View in: PubMed

Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis. Cancer. 2014 Dec 1; 120(23):3707-16. View in: PubMed

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. View in: PubMed

El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014 Feb 18; 110(4):882-7. View in: PubMed

Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs. 2013 Aug; 31(4):845-57. View in: PubMed

El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. Cancer Chemother Pharmacol. 2013 Jul; 72(1):53-64. View in: PubMed

Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 2013 Apr; 13(2):173-80. View in: PubMed

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15; 19(4):920-8. View in: PubMed

El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51. View in: PubMed

El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012 Jun; 30(3):1175-83. View in: PubMed

Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jun; 23(6):1455-64. View in: PubMed

Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. View in: PubMed

Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 1; 17(21):6934-43. View in: PubMed

Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011 Sep 1; 17(17):5783-92. View in: PubMed

Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011 Jun 28; 105(1):44-52. View in: PubMed

Labonte MJ, Yang D, Zhang W, Wilson PM, Gerger A, Bohanes PO, Ning Y, Benhaim L, El-Khoueiry R, Nagarwala YM, Kemner AM, Pishvaian MJ, Hsieh RK, Gladkov O, Urba S, Rha SY, Sakaeva D, Iqbal S, El-Khoueiry AB, Lenz H. Use of MTHFR A1298C polymorphism to predict response in a phase II international clinical trial of patients with advanced gastric (GC) or gastroesophageal junction (GEJ) adenocarcinoma treated with first-line lapatinib plus capecitabine. J Clin Oncol. 2011 May 20; 29(15_suppl):4076. View in: PubMed

Benhaim L, Gerger A, Zhang W, Yang D, Bohanes PO, Ning Y, Winder T, Labonte MJ, Wilson PM, El-Khoueiry R, El-Khoueiry AB, Iqbal S, Lenz H. Cancer stem cell gene variants associated with colon cancer recurrence. J Clin Oncol. 2011 May 20; 29(15_suppl):3612. View in: PubMed

Ladner RD, Zhang W, Labonte MJ, Yang D, Ning Y, Gerger A, Bohanes PO, Winder T, El-Khoueiry AB, Iqbal S, Petasis N, Lenz H. Prediction of tumor recurrence in stage II colon cancer through genetic variants in formyl peptide receptor 2 (FPR2). J Clin Oncol. 2011 May 20; 29(15_suppl):3604. View in: PubMed

Iqbal S, Labonte MJ, Yang D, Zhang W, Bohanes PO, Ning Y, Benhaim L, El-Khoueiry R, Wilson PM, Gerger A, El-Khoueiry AB, Lenz H. Polymorphisms in EGF a+61G, GSTP1 Ile105Val, and MTHFR A1298C to predict response and survival in a phase II study for patients with metastatic or unresectable gastric (G) or gastroesophageal junction (GEJ) cancer treated with capecitabine, oxaliplatin (XELOX), and cetuximab. J Clin Oncol. 2011 May 20; 29(15_suppl):4121. View in: PubMed

Yang D, Benhaim L, Zhang W, Bohanes PO, Ning Y, Gerger A, Labonte MJ, Groshen SG, El-Khoueiry AB, Iqbal S, Lenz H. Gender and cause-specific survival in patients with stage III colon cancer: A SEER study. J Clin Oncol. 2011 May 20; 29(15_suppl):e14006. View in: PubMed

Zhang W, Yang D, Harbison C, Khambata-Ford S, Malone DP, Ning Y, Bohanes PO, Gerger A, Labonte MJ, Benhaim L, El-Khoueiry AB, Iqbal S, Lenz H. FCGR2A H131R and FCGR3A V158F polymorphism status in mCRC patients treated with single-agent cetuximab (IMCL 0144 and CA225045) or with second-line irinotecan plus cetuximab (EPIC): A pooled statistical analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):e14025. View in: PubMed

Lenz H, Ning Y, Zhang W, Yang D, Cole S, Agafitei RD, Menendez X, Cheng P, Iqbal S, El-Khoueiry AB. Association of single-nucleotide polymorphisms (SNPs) in sodium channel, voltage-gated, type I, alpha subunit (SCN1A) with toxicity in metastatic colorectal cancer (mCRC) patients (pts) in a phase I study of patupilone (EPO906) and celebrex (C). J Clin Oncol. 2011 May 20; 29(15_suppl):e14039. View in: PubMed

Gerger A, Zhang W, Yang D, Bohanes PO, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, El-Khoueiry R, Absenger G, El-Khoueiry AB, Iqbal S, Lenz H. Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):3592. View in: PubMed

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohtomo T, Philip PA. A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2011 May 20; 29(15_suppl):4085. View in: PubMed

El-Khoueiry AB, Iqbal S, Lenz H, Gitlitz BJ, Yang D, Cole S, Duddalwar V, Garcia A. A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC). J Clin Oncol. 2011 May 20; 29(15_suppl):4124. View in: PubMed

LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011 May 15; 71(10):3635-48. View in: PubMed

Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. View in: PubMed

Zhang W, Labonte MJ, Yang D, Ning Y, Gerger A, Bohanes PO, Winder T, El-Khoueiry AB, Iqbal S, Lenz H. Use of genetic variants in formyl peptide receptor 2 (FPR2) to predict tumor recurrence in stage II colon cancer. J Clin Oncol. 2011 Feb; 29(4_suppl):408. View in: PubMed

Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. View in: PubMed

Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010 Jan; 21(1):78-86. View in: PubMed

Zhu AX, El-Khoueiry A, Llovet JM. Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S28-36. View in: PubMed

Virk N, Yang D, Lenz HJ, El-Khoueiry AB, Danenberg KD, Iqbal S. Molecular profiling in patients (pts) with upper gastrointestinal (UGI) cancers correlated with clinical outcome. J Clin Oncol. 2009 May 20; 27(15_suppl):e22042. View in: PubMed

Yang D, Pohl A, Zhang W, Lurje G, Ning Y, El-Khoueiry A, Khambata-Ford S, Langer C, Iqbal S, Lenz H. Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience. J Clin Oncol. 2009 May 20; 27(15_suppl):4022. View in: PubMed

Lenz H, Lurje G, Haiman CA, Yang D, Pohl A, Ning Y, El-Khoueiry A, Iqbal S, Zhang W. Colorectal cancer susceptibility variants and clinical outcome in adjuvant and metastatic colorectal cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):4051. View in: PubMed

El-Khoueiry AB, Pohl A, Danenberg K, Cooc J, Zhang W, Yang D, Singh H, Shriki J, Iqbal S, Lenz HJ. Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol. 2009 May 20; 27(15_suppl):4056. View in: PubMed

Winder T, Zhang W, El-Khoueiry A, Yang D, Pohl A, Lurje G, Rowinsky E, Khambata-Ford S, Langer C, Awad M, Lenz H. Association of a germ-line variant in the K-ras 3' untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. J Clin Oncol. 2009 May 20; 27(15_suppl):4061. View in: PubMed

Singh H, Pohl A, El-Khoueiry A, Lurje G, Zhang W, Yang D, Ning Y, Shriki J, Iqbal S, Lenz H. Use of genetic variants to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol. 2009 May 20; 27(15_suppl):4070. View in: PubMed

Hendifar AE, Yang D, Iqbal S, Lenz H, El-Khoueiry A. Gender disparities in hepatocellular cancer survival. J Clin Oncol. 2009 May 20; 27(15_suppl):e15517. View in: PubMed

Ottochian M, Yang D, El-Khoueiry A, Iqbal S, Pohl A, Zhang W, Ning Y, Lenz HJ. Association of gender, age, and ethnicity with survival in patients with pancreas cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):e15587. View in: PubMed

Daniels JR, Katz MD, Hart M, Fong T, Donovan JA, El-Khoueiry AB, Wallman MA. Retrospective analysis of salvage percutaneous cryoablation of hepatocellular cancer (HCC) in liver. J Clin Oncol. 2009 May 20; 27(15_suppl):e15649. View in: PubMed

Chhibar RS, Yang D, Zhang W, Lurje G, Pohl A, Ning Y, El-Khoueiry A, Iqbal S, Lenz HJ. Effect of gender and age on overall survival in patients with esophageal cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):4541. View in: PubMed

Iqbal S, Yang D, Cole S, El-Khoueiry AB, Boswell W, Agafitei R, Lujan R, Lenz HJ. Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2009 May 20; 27(15_suppl):e15077. View in: PubMed

Etzioni DA, El-Khoueiry AB, Beart RW. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008 Dec 15; 113(12):3279-89. View in: PubMed

Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008 Dec 1; 14(23):7884-95. View in: PubMed

Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008 Apr 15; 68(8):3037-42. View in: PubMed

Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. View in: PubMed

Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007 Dec; 8(12):1705-13. View in: PubMed

Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, El-Khoueiry A, Iqbal S, Sherrod AE, Lurje G, Lenz HJ. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007 Aug 20; 25(24):3726-31. View in: PubMed

Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. View in: PubMed

Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006 Oct 1; 24(28):e48. View in: PubMed

Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. View in: PubMed

Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. View in: PubMed

Shaye OS, El-Khoueiry AB, Garcia A, Wei D, Groshen S, Cole SE, Gitlitz BJ, Chung CT, Lenz HJ, Iqbal S. Phase I dose and schedule finding study of pegylated liposomal doxorubicin (D) and weekly docetaxel (T). J Clin Oncol. 2006 Jun 20; 24(18_suppl):12012. View in: PubMed

El-Khoueiry AB, Iqbal S, Singh DA, D'Andre S, Ramanathan RK, Shibata S, Yang DY, Lenz HJ, Synold T, Gandara DR. A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3595. View in: PubMed

Yang D, Vallböhmer D, Zhang W, Iqbal S, El-Khoueiry A, Gordon M, Park D, Azuma M, Groshen S, Danenberg KD, Lenz H. Intratumoral mRNA levels predict clinical outcome in patients with metastatic colorectal cancer treated in a prospective clinical trial with 5-FU and oxaliplatin. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10010. View in: PubMed

Nagashima F, Zhang W, Yang D, Gordon M, Schultheis A, Fazzone W, Azuma M, El-Khoueiry A, Iqbal S, Lenz HJ. Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3533. View in: PubMed

Azuma M, Shi MM, Jacques CJ, Barrett C, Danenberg KD, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Lenz H. Tumor VEGFA gene expression is associated with serum lactate dehydrogenase (LDH) levels and intratumoral mRNA expression of genes involved in glycolysis in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3530. View in: PubMed

El-Khoueiry AB, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006 Feb; 24(1):50-5. View in: PubMed

El-Khoueiry AB, Tagawa ST, Quinn DI, Panares R, Tsao-Wei D, Stein J, Skinner DG, Raghavan D. Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4639. View in: PubMed

Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 1995 Feb; 69(2):748-55. View in: PubMed

Powered bySC CTSI